Inhibitors of the Tyrosine Kinase Ephb4. Part 2: Structure-Based Discovery and Optimisation of 3,5-Bis Substituted Anilinopyrimidines.
Bardelle, C., Coleman, T., Cross, D., Davenport, S., Kettle, J.G., Ko, E.J., Leach, A.G., Mortlock, A., Read, J., Roberts, N.J., Robins, P., Williams, E.J.(2008) Bioorg Med Chem Lett 18: 5717
- PubMed: 18851911 
- DOI: https://doi.org/10.1016/j.bmcl.2008.09.087
- Primary Citation of Related Structures:  
2VWX, 2VWY, 2VWZ, 2VX1 - PubMed Abstract: 
Crystallographic studies of a range of 3-substituted anilinopyrimidine inhibitors of EphB4 have highlighted two alternative C-2 aniline conformations and this discovery has been exploited in the design of a highly potent series of 3,5-disubstituted anilinopyrimidines. The observed range of cellular activities has been rationalised on the basis of physicochemical and structural characteristics.
Organizational Affiliation: 
AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.